Articles and Videos
Loading...
August 16, 2021
What impacts the cost of manufacturing synthesized cannabinoids?
What affects the cost of cannabinoid manufacturing? To make rare cannabinoids commercially viable products, a high yielding and cost-effective method is required. What impacts the...
June 16, 2021
IntegraSyn™ – a flexible, high yield and cost-effective cannabinoid manufacturing system
InMed’s scientific team has developed IntegraSyn™ - a flexible, high yield and cost-effective manufacturing system to produce pharmaceutical-grade, bio-identical cannabinoids. InMed recently announced that IntegraSyn™...
Source:
BTV
June 2, 2021
Cannabinol – charting new paths for glaucoma treatment
InMed Pharmaceuticals, a clinical stage pharmaceutical company based in Vancouver, Canada, is developing rare cannabinoid–based therapeutic drug candidates for patients who may benefit from the...
May 12, 2021
Ensuring Cannabis safety – shifting from anecdotal to scientific evidence
Cannabis has been used for centuries, with evidence suggesting its medicinal use as early as 400 B.C. Interest in Cannabis’ potential medical benefits has garnered...
April 8, 2021
Current research into the potential therapeutic effects of cannabinol (CBN)
How do cannabinoids interact with the human body? There has been a significant growth in interest and research into the potential therapeutic properties of cannabinoids....
February 18, 2021
InMed’s CEO Eric A. Adams presents at Edison Open House: Global Healthcare 2021
InMed Pharmaceuticals CEO, Eric A. Adams, is interviewed by Science Journalist and Broadcaster Vivienne Parry Obe at the Edison Open House: Global Healthcare Conference 2021....
Source:
Edison TV